Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients
Status:
Recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
Some patients with bipolar disorder show broad cognitive impairments (e.g. difficulty with
concentration, problem solving, memory etc.) that persist during euthymia (no symptoms of
depression or mania) despite remission of mood symptoms. Cognitive deficits (significant
cognitive impairments) in bipolar disorder are associated with impairments in everyday
functioning and quality of life. Thus, improving cognitive functioning is an important
treatment goal in people with bipolar disorder. In a recent study, investigators have
demonstrated that lurasidone; an atypical antipsychotic was more effective than treatment as
usual in improving cognition. The study will examine the efficacy of Cariprazine (VRAYLAR®)
in improving cognition in patients with bipolar disorder. Cariprazine is a novel atypical
antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for
treatment of schizophrenia, manic or mixed, and depressive episodes associated with bipolar I
disorder. This study is a randomized (like the flip of a coin), double-blind (participant and
the study team will not know which treatment arm participant will receive) study in which 30
participants will be randomized across two sites in Canada.